DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Bulletin > Acta Medica Nagasakiensia > Volume 54, No. 2 >

Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice


File Description SizeFormat
acta_54_2_33.pdf298.56 kBAdobe PDFView/Open

Title: Oral Administration of Recombinant Live Yeast Producing Altered Peptide Ligand Derived from Insulin B:9-23 Peptide Linked to Cholera Toxin B Subunit Suppresses Development of Autoimmune Diabetes in NOD Mice
Authors: Zhou, Hongbo / Abiru, Norio / Arakawa, Takeshi / Sakima, Rina / Miyata, Takeshi / Kobayashi, Masakazu / Fukushima, Keiko / Kawasaki, Eiji / Yamasaki, Hironori / Eguchi, Katsumi
Issue Date: Dec-2009
Publisher: Nagasaki University School of Medicine
Citation: Acta medica Nagasakiensia, 54(2), pp.33-38 ; 2009
Abstract: Insulin is a major autoantigen responsible for the pathogenesis of type 1 diabetes, and its B-chain peptide B:9-23 has been suggested to contain critically important epitopes in the NOD mouse. We have previously demonstrated that the altered peptide ligand of B:9-23 peptide with alanine substitutions at positions 16 and 19 (A16,19 APL) suppresses insulitis and reduces the incidence of diabetes when administered intranasally together with cholera toxin (CT). In this study, we extended the previous findings to determine whether mucosal administration of the A16,19APL without the use of toxic CT is efficacious for diabetes prevention. To this end,we linked the A16,19APL to the C-terminus of non-toxic cholera toxin (CTB) B subunit and the chimeric fusion protein was produced in methyloprophic yeast Pichia pastoris. Although intranasal administration of the recombinant CTB-A16,19APL fusion protein extracted fromthe yeast cells failed to prevent the progression to diabetes, oral administration of the live yeast cells producing the chimeric protein resulted in more than 50% reduction of the development of diabetes, albeit the fact that protective efficacy did not reach the significance level by life table analysis (P= 0.08). Furthermore, the expression of insulin autoantibodies was not altered throughout the course of oral immunization experiment. These results demonstrated that the efficacy of recombinant CTB-A16,19APL for oral immunization has much room for improvement. Nevertheless, oral administration of recombinant yeast or other edible materials such as food plants engineered to produce altered autoantigenic peptide could potentially become a novel non-invasive immunotherapeutic strategy for type 1 diabetes. (250 word)
Keywords: Type 1 diabetes / Insulin / Oral tolerance / Yeast / Altered peptide ligand / Cholera toxin B subunit
URI: http://hdl.handle.net/10069/22686
ISSN: 00016055
Relational Links: http://joi.jlc.jst.go.jp/JST.JSTAGE/amn/54.33
Type: Departmental Bulletin Paper
Text Version: publisher
Appears in Collections:Volume 54, No. 2

Citable URI : http://hdl.handle.net/10069/22686

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace